WO2021037290A3 - 一种融合多肽及其应用 - Google Patents

一种融合多肽及其应用 Download PDF

Info

Publication number
WO2021037290A3
WO2021037290A3 PCT/CN2020/123552 CN2020123552W WO2021037290A3 WO 2021037290 A3 WO2021037290 A3 WO 2021037290A3 CN 2020123552 W CN2020123552 W CN 2020123552W WO 2021037290 A3 WO2021037290 A3 WO 2021037290A3
Authority
WO
WIPO (PCT)
Prior art keywords
fibrosis
ser
leu
lys
asp
Prior art date
Application number
PCT/CN2020/123552
Other languages
English (en)
French (fr)
Other versions
WO2021037290A2 (zh
Inventor
康志安
Original Assignee
南京安吉生物科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 南京安吉生物科技有限公司 filed Critical 南京安吉生物科技有限公司
Priority to AU2020339572A priority Critical patent/AU2020339572A1/en
Priority to CA3149590A priority patent/CA3149590A1/en
Priority to GB2201003.7A priority patent/GB2600594A/en
Priority to US17/636,232 priority patent/US20220332763A1/en
Publication of WO2021037290A2 publication Critical patent/WO2021037290A2/zh
Publication of WO2021037290A3 publication Critical patent/WO2021037290A3/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

提供了一种融合多肽，该多肽中含有结构域N-Acetyl-Ser-Asp-Lys-Pro、Ser-Asp-Lys-Pro和Thr-Ser-Leu-Asp-Ala-Ser-Ile-Ile-Trp-Ala-Met-Met-Gin-Asn,Leu-Ser-Lys-Leu,或者上述结构域中突变其中的任意氨基酸，结构域之间可以柔性linker连接，可用于治疗各种纤维化疾病以及肿瘤，纤维化疾病包括肺纤维化、肝纤维化、皮肤纤维化、肾纤维化和心肌纤维化。
PCT/CN2020/123552 2019-08-27 2020-10-26 一种融合多肽及其应用 WO2021037290A2 (zh)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2020339572A AU2020339572A1 (en) 2019-08-27 2020-10-26 Fusion polypeptide and use thereof
CA3149590A CA3149590A1 (en) 2019-08-27 2020-10-26 Fused polypeptide and use thereof
GB2201003.7A GB2600594A (en) 2019-08-27 2020-10-26 Fused polypeptide and use thereof
US17/636,232 US20220332763A1 (en) 2019-08-27 2020-10-26 Fused polypeptide and use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201910794499.0 2019-08-27
CN201910794499.0A CN110483648A (zh) 2019-08-27 2019-08-27 一种融合多肽及其应用

Publications (2)

Publication Number Publication Date
WO2021037290A2 WO2021037290A2 (zh) 2021-03-04
WO2021037290A3 true WO2021037290A3 (zh) 2021-04-15

Family

ID=68553536

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2020/123552 WO2021037290A2 (zh) 2019-08-27 2020-10-26 一种融合多肽及其应用

Country Status (6)

Country Link
US (1) US20220332763A1 (zh)
CN (1) CN110483648A (zh)
AU (1) AU2020339572A1 (zh)
CA (1) CA3149590A1 (zh)
GB (1) GB2600594A (zh)
WO (1) WO2021037290A2 (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110483648A (zh) * 2019-08-27 2019-11-22 南京安吉生物科技有限公司 一种融合多肽及其应用
CN111184856B (zh) * 2020-02-26 2023-12-01 南方医科大学南方医院 小分子多肽tp-7在制备治疗慢性肾脏病药物中的用途
CN117720620A (zh) * 2023-12-13 2024-03-19 无锡市儿童医院 小分子多肽和其药物组合物、其制药用途

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1328569A (zh) * 1998-11-24 2001-12-26 纳瓦拉公司科学与技术研究所 TGFβ1－抑制肽
CN101340927A (zh) * 2005-10-24 2009-01-07 西玛生物医学信息公司 TGF-β1抑制性多肽在制备免疫反应调节剂上的用途
WO2009149201A1 (en) * 2008-06-03 2009-12-10 Cedars-Sinai Medical Center Methods of treatment for pulmonary fibrosis
WO2010141609A1 (en) * 2009-06-02 2010-12-09 Cedars-Sinai Medical Center Use of angiotensin converting enzyme (ace) domain specific inhibitors to inhibit or enhance cytokine production and alter immune response
CN102307598A (zh) * 2009-02-05 2012-01-04 迪格纳生物技术公司 TGF-β1抑制肽的药物制剂
CN102341115A (zh) * 2009-03-06 2012-02-01 医姿挺有限公司 用于预防或治疗性处理初始阶段的皮肤肿瘤的肽
CN102791283A (zh) * 2010-02-22 2012-11-21 西马生物医学计划公司 转化生长因子-β1(TGF-β1)抑制剂肽治疗角膜纤维化和/或角膜浑浊的应用
CN105658229A (zh) * 2013-05-10 2016-06-08 南方研究所 通过抑制TGF-β活性治疗疾病的化合物、组合物和方法
CN110483648A (zh) * 2019-08-27 2019-11-22 南京安吉生物科技有限公司 一种融合多肽及其应用

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1328569A (zh) * 1998-11-24 2001-12-26 纳瓦拉公司科学与技术研究所 TGFβ1－抑制肽
CN101340927A (zh) * 2005-10-24 2009-01-07 西玛生物医学信息公司 TGF-β1抑制性多肽在制备免疫反应调节剂上的用途
WO2009149201A1 (en) * 2008-06-03 2009-12-10 Cedars-Sinai Medical Center Methods of treatment for pulmonary fibrosis
CN102307598A (zh) * 2009-02-05 2012-01-04 迪格纳生物技术公司 TGF-β1抑制肽的药物制剂
CN102341115A (zh) * 2009-03-06 2012-02-01 医姿挺有限公司 用于预防或治疗性处理初始阶段的皮肤肿瘤的肽
WO2010141609A1 (en) * 2009-06-02 2010-12-09 Cedars-Sinai Medical Center Use of angiotensin converting enzyme (ace) domain specific inhibitors to inhibit or enhance cytokine production and alter immune response
CN102791283A (zh) * 2010-02-22 2012-11-21 西马生物医学计划公司 转化生长因子-β1(TGF-β1)抑制剂肽治疗角膜纤维化和/或角膜浑浊的应用
CN105658229A (zh) * 2013-05-10 2016-06-08 南方研究所 通过抑制TGF-β活性治疗疾病的化合物、组合物和方法
CN110483648A (zh) * 2019-08-27 2019-11-22 南京安吉生物科技有限公司 一种融合多肽及其应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
XU, HONG: "The New Target of Ac-SDKP Anti-silicotic Effect: Myofibroblasts Differentiation and Screen of Differential Proteins by Proteomics", CHINA DOCTORAL DISSERTATIONS FULL-TEXT DATABASE, MEDICINE AND HEALTH SCIENCES, 15 January 2013 (2013-01-15), XP055798926 *
YUAN, WEN: "Inhibitory Effect of LSKL Peptide on Subarachnoid Fibrosis after SAH", MEDICINE AND HEALTH SCIENCES, CHINESE MASTER’S THESES FULL-TEXT DATABASE, 1 May 2014 (2014-05-01), pages 1 - 50, XP055798930, [retrieved on 20210426] *

Also Published As

Publication number Publication date
CA3149590A1 (en) 2021-03-04
GB202201003D0 (en) 2022-03-09
GB2600594A (en) 2022-05-04
CN110483648A (zh) 2019-11-22
AU2020339572A1 (en) 2022-03-10
WO2021037290A2 (zh) 2021-03-04
US20220332763A1 (en) 2022-10-20

Similar Documents

Publication Publication Date Title
WO2021037290A3 (zh) 一种融合多肽及其应用
WO2020014285A3 (en) Fusion constructs and methods of using thereof
KR102622541B1 (ko) 속눈썹 어플리케이터, 자성 인조 속눈썹, 및 그 사용 방법
DE69101547D1 (de) Herzschrittmacher mit im Kreislauf platzierten Blutdruckaufnehmer zur Anzeige der Körperlage eines Patienten.
ATE538136T1 (de) Antikörper gegen connective tissue growth factor
WO1996019580A3 (en) Telomerase protein component
WO2020103961A9 (zh) 一种脑部肿瘤靶向肽及其应用
USD865071S1 (en) Rotating fidget device
WO2021037289A3 (zh) 一种重组融合多肽及其应用
WO2021181233A3 (en) Cd80-fc fusion protein and uses thereof
JPS58190429A (ja) 超音波アプリケ−タ
IT1048987B (it) Procedimento per la preparazione di aggregati macroscopici a base di tecnezio 99m albumina e stagno stannoso e prodotto ottenuto
EP4282490A3 (en) Fibronectin-binding peptides for use in tumor or fibrosis diagnosis and therapy
NO883834L (no) Nye hiv-proteiner og peptider anvendelige i diagnosen, profylaksen eller terapien av aids.
WO2020154714A3 (en) Systems and methods for modulating crispr activity
Harken A review of the activities of the thoracic center for the III and IV hospital groups, 160th General Hospital European Theater of Operations, June 10, 1944 to Jan. 1, 1945
EP3801235A4 (en) PROCEDURE FOR VISUALIZING BODY SURFACE OF A PATIENT AND DETERMINING COORDINATES OF ECG ELECTRODES DURING NON-INVASIVE ELECTROPHYSIOLOGICAL IMAGING OF THE HEART
WO2004017992A3 (en) Ptk7 protein involvement in carcinoma
MX2022003531A (es) Polipeptidos de fusion dap10/dap12.
WO2021037291A3 (zh) 具有多功能活性的融合多肽及其应用
WO2020087051A8 (en) Targeted chondroitinase abc fusion proteins and complexes thereof
IT7924643A0 (it) Giunzione d'angolo specie perl'impiego in incastellature per esposizioni, divisori di locali osimilari.
USD941031S1 (en) Paint brush handle with attached scraper and magnet
Alexander et al. Intravesical growth of murine bladder tumors assessed by transrectal ultrasound
US57320A (en) Improved broom-head

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20859367

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 202201003

Country of ref document: GB

Kind code of ref document: A

Free format text: PCT FILING DATE = 20201026

ENP Entry into the national phase

Ref document number: 3149590

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2020339572

Country of ref document: AU

Date of ref document: 20201026

Kind code of ref document: A

122 Ep: pct application non-entry in european phase

Ref document number: 20859367

Country of ref document: EP

Kind code of ref document: A2